NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Recruiting · Phase 2 · NCT06450041
Conditions: Neuroblastoma
At a glance
- Research payments reported, 2025
- $53,114
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 62
About the trial
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium (with Nationwide Children's Hospital, United Therapeutics, Children's Neuroblastoma Cancer Fund)
- Tested
- Universal Donor (UD) TGFβi NK Cells (drug), Temozolomide (drug), Irinotecan (drug), Dinutuximab (drug), GM-CSF (drug)
- Dates
- Started 2024-12-16; completion 2038-12
- Results posted
- Not yet
This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
From ClinicalTrials.gov, last updated 2026-07-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
United Therapeutics Corporation reported $53,114 in research payments for this study in 2025 (3 payments).
Products named: Unituxin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.